(Reuters) – The European Union’s medicine regulator mentioned it was evaluating a advertising and marketing authorisation for an antibody cocktail developed by Roche and Regeneron (NASDAQ:) for the therapy and prevention of COVID-19 in individuals above the age of 12.
The European Medicines Company mentioned on Monday it’s going to assess the dangers and advantages of the drug, known as Ronapreve, and that it may situation an opinion inside two months. The company has already began a rolling evaluate of the therapy.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury because of reliance on the data together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding varieties attainable.
Comply with News Everything for News At this time, Breaking News, Newest News, World News, Breaking News Headlines, Nationwide News, At this time’s News
#assesses #RegeneronRoche #COVID19 #antibody #cocktail #authorisation #Reuters